Scholarlink

Purpose <p>Relatlimab (rela) with nivolumab (nivo) has demonstrated durable responses in pre-treated advanced melanoma. Intracranial responses have been demonstrated with the combination of ipilimumab (ipi) with nivo in melanoma brain metastases (MBM). We sought to characterize intracranial outcomes in patients treated with nivo/rela following ipi/nivo.</p> Patients and Methods <p>A retrospective analysis of patients who received nivo/rela with MBM was performed. Patients had prior ipi/nivo and active MBM. The primary endpoint was central nervous system progression free survival (CNS-PFS). Secondary endpoints included overall survival (OS), extracranial-PFS, and safety with local therapy.</p> Results <p>We identified 24 patients, with a median follow-up of 14.2-months. Median age was 72 (range 31–85), 75% were male, and 29% had neurologic symptoms. The median total prior lines of systemic therapy was 3 (range: 1–8), and in the metastatic setting 2 (range: 1–8). Eighteen (75%) patients received local therapy with nivo/rela, 16 (67%) stereotactic radiosurgery (SRS), 2 (8%) whole brain radiation therapy, and 3 (13%) surgery. Median CNS-PFS was 5.3 months (95% CI 2.5–24.2) and median extracranial-PFS was 2.8 months (95% CI 1.9–15.7). Median OS was 12.1 months (95% CI 5.3–24.2), with a 12-month rate of 55%. No patients developed symptomatic radiation necrosis following SRS.</p> Conclusion <p>Nivo/rela demonstrates moderate efficacy for MBM after ipi/nivo. Concurrent local therapy appears safe alongside nivo/rela.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression

  • 期刊论文

  • 发表日期：

    2026年3月9日

查看全文
  • Vaseem M. Khatri,
  • Michael Aboujaoude,
  • Lilit Karapetyan,
  • Ahmad A. Tarhini,
  • Andrew S. Brohl,
  • Zeynep Eroglu,
  • Joseph Markowitz,
  • Kareem Rayn,
  • Nikhil I. Khushalani,
  • Evan J. Wuthrick,
  • H. Michael. Yu,
  • Daniel E. Oliver,
  • Kamran A. Ahmed

摘要

Purpose

Relatlimab (rela) with nivolumab (nivo) has demonstrated durable responses in pre-treated advanced melanoma. Intracranial responses have been demonstrated with the combination of ipilimumab (ipi) with nivo in melanoma brain metastases (MBM). We sought to characterize intracranial outcomes in patients treated with nivo/rela following ipi/nivo.

Patients and Methods

A retrospective analysis of patients who received nivo/rela with MBM was performed. Patients had prior ipi/nivo and active MBM. The primary endpoint was central nervous system progression free survival (CNS-PFS). Secondary endpoints included overall survival (OS), extracranial-PFS, and safety with local therapy.

Results

We identified 24 patients, with a median follow-up of 14.2-months. Median age was 72 (range 31–85), 75% were male, and 29% had neurologic symptoms. The median total prior lines of systemic therapy was 3 (range: 1–8), and in the metastatic setting 2 (range: 1–8). Eighteen (75%) patients received local therapy with nivo/rela, 16 (67%) stereotactic radiosurgery (SRS), 2 (8%) whole brain radiation therapy, and 3 (13%) surgery. Median CNS-PFS was 5.3 months (95% CI 2.5–24.2) and median extracranial-PFS was 2.8 months (95% CI 1.9–15.7). Median OS was 12.1 months (95% CI 5.3–24.2), with a 12-month rate of 55%. No patients developed symptomatic radiation necrosis following SRS.

Conclusion

Nivo/rela demonstrates moderate efficacy for MBM after ipi/nivo. Concurrent local therapy appears safe alongside nivo/rela.